Histogenics Corp. (HSGX) Upgraded by Zacks Investment Research to “Buy”
Zacks Investment Research upgraded shares of Histogenics Corp. (NASDAQ:HSGX) from a hold rating to a buy rating in a research report sent to investors on Monday morning. The firm currently has $2.50 target price on the stock.
According to Zacks, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. “
Other research analysts have also recently issued reports about the company. BTIG Research upgraded Histogenics Corp. from a neutral rating to a buy rating and set a $3.50 price objective for the company in a research note on Thursday, August 11th. Needham & Company LLC lifted their price target on Histogenics Corp. from $8.00 to $11.00 and gave the company a buy rating in a research report on Monday, September 19th. Finally, William Blair cut Histogenics Corp. from an outperform rating to a market perform rating in a research report on Wednesday, September 7th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of $6.25.
Histogenics Corp. (NASDAQ:HSGX) opened at 2.28 on Monday. The stock’s 50 day moving average price is $2.66 and its 200-day moving average price is $2.40. The company’s market capitalization is $30.26 million. Histogenics Corp. has a 52-week low of $1.39 and a 52-week high of $4.47.
Histogenics Corp. (NASDAQ:HSGX) last announced its quarterly earnings data on Thursday, November 10th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.21. During the same period in the previous year, the firm posted ($0.61) earnings per share. Analysts predict that Histogenics Corp. will post ($2.28) earnings per share for the current fiscal year.
In other Histogenics Corp. news, major shareholder Split Rock Partners Ii, Lp acquired 276,801 shares of the business’s stock in a transaction dated Thursday, September 29th. The stock was acquired at an average cost of $2.25 per share, for a total transaction of $622,802.25. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 16.00% of the stock is owned by insiders.
An institutional investor recently raised its position in Histogenics Corp. stock. Carl Domino Inc boosted its position in Histogenics Corp. (NASDAQ:HSGX) by 24.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 34,011 shares of the company’s stock after buying an additional 6,700 shares during the period. Carl Domino Inc owned about 0.26% of Histogenics Corp. worth $110,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 32.29% of the company’s stock.
Histogenics Corp. Company Profile
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Receive News & Stock Ratings for Histogenics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corp. and related stocks with our FREE daily email newsletter.